Aura Biosciences (AURA) vs Candel Therapeutics (CADL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Candel Therapeutics (CADL) has outperformed Aura Biosciences (AURA) over the past year, gaining 53.3% versus a gain of 6.8%. Candel Therapeutics is the larger company by market cap ($756.8 million vs $678.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AURA | CADL |
|---|---|---|
| Share price | $6.55 | $9.89 |
| Market cap | $678.75M | $756.77M |
| 1-day change | +0.61% | +2.38% |
| YTD return | +19.36% | +70.97% |
| 1-year return | +6.81% | +53.33% |
| 5-year return | — | -1.73% |
| EPS (TTM) | $-1.75 | $-1.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $9.54 | $14.00 |
| 52-week low | $4.73 | $4.35 |
| Distance from 52-week high | -31.36% | -29.36% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +153.63% | +119.92% |
| Average volume | 756.20K | 1.21M |
| Shares outstanding | 103.70M | 76.52M |
| Employees | 113 | 55 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CADL has outperformed AURA by 46.5 percentage points over the past year.
About Aura Biosciences
AURA stock →Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 113 employees
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
AURA vs CADL FAQ
Which is bigger, Aura Biosciences or Candel Therapeutics?
Candel Therapeutics (CADL) is larger, with a market capitalization of $756.77M compared with $678.75M for Aura Biosciences (AURA).
Which stock has performed better over the past year, AURA or CADL?
CADL returned +53.33% over the past 12 months, compared with +6.81% for AURA (price return, excluding dividends). Past performance does not predict future results.
Are Aura Biosciences and Candel Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.